Programming Grants to Accompany NEH on the Road Exhibitions

Deadline :  9-26-2016

Funding Opportunity :  RFA-CA-16-004

CFDA :  93.394|000000

Agency :  Department of Health and Human Services

Contact :  NIH OER Webmaster
This email address is being protected from spambots. You need JavaScript enabled to view it.

                This email address is being protected from spambots. You need JavaScript enabled to view it.

Eligibility :  State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Native American Tribal Governments (Federally recognized)
Public Housing Authorities/Indian Housing Authorities
Native American Tribal Organizations (other than Federally recognized tribal governments)
Nonprofits Having a 501 (c) (3) Status with the IRS (other than institutions of higher education)
Nonprofits that do not have a 501 (c) (3) status with the IRS (other than institutions of higher education)
Private institutions of higher education
For-profit organizations other than small business
Small businesses
Others

Details :  
This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the advanced development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens. This FOA solicits R33 applications where proof-of-principle for the emerging technology or methodology has been provided with supportive preliminary data demonstrating a novel capability for maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this FOA and will not be reviewed.